TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023.
- Revenues of $3.7 billion
- GAAP loss per share of $0.18
- Non-GAAP diluted EPS of $0.40
- Cash flow used in operating activities of $145 million
- Free cash flow of $41 million
- Non-GAAP gross profit margin of 49.1% was mainly impacted by an unfavorable portfolio mix and an increase in COGS due to inflationary pressure. We expect our gross profit margin to improve in the coming quarters due to improved portfolio mix driven by our innovative products, namely AUSTEDO®, AJOVY® and UZEDY™, as well as by lower COGS, driven by supply chain enhancements and easing of certain elements of inflationary pressure.
-
Full year 2023 business outlook reaffirmed:
- Revenues of $14.8 – $15.4 billion
- Adjusted EBITDA of $4.5 – $4.9 billion
- Non-GAAP diluted EPS of $2.25 – $2.55
- Free cash flow of $1.7 – $2.1 billion
Mr. Richard Francis, Teva’s President and CEO, said, “I am pleased to report that our revenues for the first quarter reached $3.7 billion, marking a 4% increase in local currency terms, compared to the first quarter of 2022: We have seen growth across all regions – Europe is experiencing a solid 9% increase, International Markets an 8% increase, and North America is up 2%.”
Mr. Francis continued, “Our innovative brands performed well this quarter – AUSTEDO grew 10% year-over-year and AJOVY grew 35% across all regions in local currency. We are also excited about the recent approvals of AUSTEDO XR, the new once-daily formulation for AUSTEDO, and UZEDY (risperidone), our new long-acting injectable treatment for schizophrenia in adults. While we are seeing some positive tailwinds, we are also taking decisive actions to address some headwinds, mainly through improved portfolio mix driven by our innovative products and supply chain enhancements. We expect these actions will improve our gross profit margin in the coming quarters, and today, we are reaffirming our 2023 outlook which was provided in February.
As we prepare to launch our new strategy next week, I am filled with enthusiasm and optimism. This strategy will build on Teva’s strong foundations, key strengths, and sets the stage for long-term growth. We have worked hard over the last few months to challenge ourselves, look at how the market is evolving and how we can create substantial value both for Teva and for patients. I am really excited about the outcome – a new roadmap where we will make decisive choices and focus our resources to drive growth and innovation.”
First Quarter 2023 Consolidated Results
Revenues in the first quarter of 2023 were $3,661 million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and International Markets segments, certain innovative products primarily AUSTEDO and AJOVY, as well as from Anda in our North America segment, partially offset by lower revenues from generic products in our North America segment, API sales to third parties and BENDEKA® and TREANDA® in our North America segment.
Exchange rate movements during the first quarter of 2023, including hedging effects, negatively impacted our revenues by $128 million compared to the first quarter of 2022. Exchange rate movements during the first quarter of 2023, including hedging effects, negatively impacted our operating income and non-GAAP operating income by $32 million and $33 million, respectively, compared to the first quarter of 2022.
Gross profit was $1,582 million in the first quarter of 2023, a decrease of 9% compared to the first quarter of 2022. Gross profit margin was 43.2% in the first quarter of 2023, compared to 47.5% in the first quarter of 2022. Non-GAAP gross profit was $1,796 million in the first quarter of 2023, a decrease of 10% compared to the first quarter of 2022. Non-GAAP gross profit margin was 49.1% in the first quarter of 2023, compared to 54.2% in the first quarter of 2022. This decrease in both gross profit margin and non- GAAP gross profit margin was mainly driven by rising costs due to inflationary and other macroeconomic pressures, an increase in revenues with lower profitability from Anda in our North America segment, lower revenues from COPAXONE® and BENDEKA and TREANDA, and an unfavorable impact of hedging activities, partially offset by higher revenues from AUSTEDO and AJOVY.
Research and Development (R&D) expenses in the first quarter of 2023 were $234 million, an increase of 4% compared to $225 million, in the first quarter of 2022, mainly due to an increase in neuroscience (mainly neuropsychiatry) and immunology as well as various generics and biosimilar products.
Selling and Marketing (S&M) expenses in the first quarter of 2023 were $546 million, a decrease of 6% compared to the first quarter of 2022.
General and Administrative (G&A) expenses in the first quarter of 2023 were $296 million, flat compared to the first quarter of 2022.
Other income in the first quarter of 2023 was $2 million, compared to $52 million in the first quarter of 2022. Other income in the first quarter of 2022 was mainly the result of settlement proceeds in our International Markets segment.
Operating income in the first quarter of 2023 was $2 million, compared to an operating loss of $713 million in the first quarter of 2022. Operating income as a percentage of revenues was 0.1% in the first quarter of 2023, compared to operating loss as a percentage of revenues of 19.5% in the first quarter of 2022. The increase in operating income and in operating margin in the first quarter of 2023 was mainly due to higher legal settlements and loss contingencies in the first quarter of 2022. Non-GAAP operating income in the first quarter of 2023 was $785 million representing a non-GAAP operating margin of 21.4%, compared to non-GAAP operating income of $1,013 million, representing a non-GAAP operating margin of 27.7%, in the first quarter of 2022. The decrease in non-GAAP operating margin in the first quarter of 2023 was mainly impacted by lower non-GAAP gross profit margin as discussed above, as well as higher other income in the first quarter of 2022, which primarily included settlement proceeds in our International Markets segment.
Adjusted EBITDA was $899 million in the first quarter of 2023, a decrease of 21%, compared to $1,135 million in the first quarter of 2022.
Financial expenses, net in the first quarter of 2023 were $260 million, compared to $258 million in the first quarter of 2022. Financial expenses, net in the first quarter of 2023 and 2022 were mainly comprised of interest expenses of $260 million and $238 million, respectively.
In the first quarter of 2023, we recognized a tax benefit of $19 million on a pre-tax loss of $258 million. In the first quarter of 2022, we recognized a tax expense of $2 million on a pre-tax loss of $971 million.
Non-GAAP tax rate in the first quarter of 2023 was 15.5%, compared to 18.5% in the first quarter of 2022. Our non-GAAP tax rate in the first quarter of 2023 was mainly affected by the geographic mix of earnings and interest expense disallowances.
We expect our annual non-GAAP tax rate for 2023 to be between 14%-17%, higher than our non-GAAP tax rate for 2022, which was 11.7%, mainly due to the effect of a portion of the realization of losses related to an investment in one of our U.S. subsidiaries in 2022.
Net loss attributable to Teva and loss per share in the first quarter of 2023 were $205 million and $0.18, respectively, compared to $955 million and $0.86, respectively, in the first quarter of 2022. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the first quarter of 2023 were $457 million and $0.40, respectively, compared to $609 million and $0.55, respectively, in the first quarter of 2022.
As of March 31, 2023 and 2022, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,158 million and 1,145 million, respectively.
Non-GAAP information: net non-GAAP adjustments in the first quarter of 2023 were $661 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the first quarter of 2023 were adjusted to exclude the following items:
- Amortization of purchased intangible assets of $165 million, of which $145 million is included in cost of sales and the remaining $20 million in S&M expenses;
- Legal settlements and loss contingencies of $233 million;
- Impairment of long-lived assets of $188 million;
- Restructuring expenses of $56 million;
- Equity compensation expenses of $32 million;
- Accelerated depreciation of $25 million;
- Financial expenses of $23 million;
- Contingent consideration expense of $20 million;
- Costs related to regulatory actions taken in facilities of $1 million;
- Other non-GAAP items of $63 million;
- Items attributable to non-controlling interests of $40 million; and
- Corresponding tax effects and unusual tax items of $104 million.
We believe that excluding such items facilitates investors’ understanding of our business.
For further information, see the tables below for a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and the information under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow used in operating activities during the first quarter of 2023 was $145 million, compared to $49 million in the first quarter of 2022. The higher cash flow used in the first quarter of 2023 resulted mainly from lower profit and changes in working capital items, including an increase in accounts receivables net of SR&A, partially offset by an increase in accounts payables.
During the first quarter of 2023, we generated free cash flow of $41 million, which we define as comprising $145 million in cash flow used in operating activities, $323 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $2 million in proceeds from divestitures of businesses and other assets, partially offset by $139 million in cash used for capital investment. During the first quarter of 2022, we generated free cash flow of $117 million, which we define as comprising $49 million in cash flow used in operating activities, $305 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $25 million in proceeds from divestitures of businesses and other assets, partially offset by $157 million in cash used for capital investment and $7 million in cash used for acquisition of businesses, net of cash acquired. The decrease in the first quarter of 2023, resulted mainly from higher cash flow used in operating activities, as discussed above.
As of March 31, 2023, our debt was $20,691 million, compared to $21,212 million as of December 31, 2022. This decrease was mainly due to $646 million senior notes repaid at maturity, partially offset by $176 million of exchange rate fluctuations. Additionally, during the first quarter of 2023, we repurchased $2,506 million aggregate principal amount of notes upon consummation of a cash tender offer, and issued $2,445 million of sustainability-linked senior notes, net of issuance costs. The portion of our total debt classified as short-term as of March 31, 2023 was 5%, compared to 10% as of December 31, 2022. Our average debt maturity was approximately 6.4 years as of March 31, 2023, compared to 5.8 years as of December 31, 2022.
Segment Results for the first Quarter of 2023
North America Segment
Our North America segment includes the United States and Canada.
The following table presents revenues, expenses and profit for our North America segment for the three months ended March 31, 2023 and 2022:
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
||||||
|
|
2023 |
|
2022 |
||||
|
|
(U.S. $ in millions / % of Segment Revenues) |
||||||
|
Revenues |
$ |
1,766 |
100% |
$ |
1,737 |
100% |
|
|
Gross profit |
|
812 |
46.0% |
|
890 |
51.2% |
|
|
R&D expenses |
|
156 |
8.8% |
|
143 |
8.2% |
|
|
S&M expenses |
|
223 |
12.6% |
|
245 |
14.1% |
|
|
G&A expenses |
|
102 |
5.8% |
|
112 |
6.4% |
|
|
Other income |
|
(1) |
§ |
|
(11) |
(0.7%) |
|
|
Segment profit* |
$ |
332 |
18.8% |
$ |
402 |
23.1% |
|
|
|
|
|
|
|
|
||
|
* Segment profit does not include amortization and certain other items. |
|||||||
|
§ Represents an amount less than 0.5%. |
|||||||
Revenues from our North America segment in the first quarter of 2023 were $1,766 million, an increase of $29 million, or 2%, compared to the first quarter of 2022, mainly due to higher revenues from certain innovative products, primarily AUSTEDO and AJOVY, as well as Anda, partially offset by lower revenues from generic products and BENDEKA and TREANDA.
Revenues in the United States, our largest market, were $1,677 million in the first quarter of 2023, an increase of $39 million or 2% compared to the first quarter of 2022.
Revenues by Major Products and Activities
The following table presents revenues for our North America segment by major products and activities for the three months ended March 31, 2023 and 2022:
|
|
|
|
|
|
||||
|
|
|
Three months ended March 31, |
|
Percentage Change |
||||
|
|
|
2023 |
|
2022 |
|
2023-2022 |
||
|
|
|
(U.S. $ in millions) |
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
Generic products |
|
$ |
824 |
|
$ |
899 |
|
(8%) |
|
AJOVY |
|
|
49 |
|
|
36 |
|
36% |
|
AUSTEDO |
|
|
170 |
|
|
154 |
|
10% |
|
BENDEKA and TREANDA |
|
|
63 |
|
|
82 |
|
(23%) |
|
COPAXONE |
|
|
76 |
|
|
86 |
|
(12%) |
|
Anda |
|
|
424 |
|
|
342 |
|
24% |
|
Other (*) |
|
|
160 |
|
|
139 |
|
15% |
|
Total |
|
$ |
1,766 |
|
$ |
1,737 |
|
2% |
____________________
(*) Other revenues in the first quarter of 2023 increased mainly due to a reduction in estimated liabilities in connection with ProAir® HFA following its discontinuation on October 1, 2022.
Generic products revenues in our North America segment (including biosimilars) in the first quarter of 2023 were $824 million, a decrease of 8% compared to the first quarter of 2022, mainly due to increased competition to parts of our portfolio.
On March 9, 2023, Teva and Natco Pharma Ltd. announced the launch of additional strengths for lenalidomide capsules (the generic equivalent of Revlimid®) in the U.S., in 2.5 mg and 20 mg strengths.
In the first quarter of 2023, our total prescriptions for generic products were approximately 81 million (based on trailing twelve months), representing 8.3% of total U.S. generic prescriptions according to IQVIA data.
AJOVY revenues in our North America segment in the first quarter of 2023 increased by 36% to $49 million, compared to the first quarter of 2022, mainly due to growth in volume. In the first quarter of 2023, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 24.5% compared to 23.9% in the first quarter of 2022.
AUSTEDO revenues in our North America segment in the first quarter of 2023 increased by 10%, to $170 million, compared to $154 million in the first quarter of 2022, mainly due to growth in volume.
AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023. AUSTEDO XR is a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, additional to the currently marketed twice-daily AUSTEDO.
On April 28, 2023, the FDA approved UZEDYTM (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is expected to be available in the U.S. in the coming weeks.
BENDEKA and TREANDA combined revenues in our North America segment in the first quarter of 2023 decreased by 23% to $63 million, compared to the first quarter of 2022, mainly due to generic bendamustine product entry into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022.
COPAXONE revenues in our North America segment in the first quarter of 2023 decreased by 12% to $76 million, compared to the first quarter of 2022, mainly due to generic competition in the United States and a decrease in glatiramer acetate market share due to availability of alternative therapies.
Anda revenues from third-party products in our North America segment in the first quarter of 2023 increased by 24% to $424 million, compared to $342 million in the first quarter of 2022, mainly due to higher demand.
North America Gross Profit
Gross profit from our North America segment in the first quarter of 2023 was $812 million, a decrease of 9%, compared to $890 million in the first quarter of 2022.
Gross profit margin for our North America segment in the first quarter of 2023 decreased to 46.0%, compared to 51.2% in the first quarter of 2022. This decrease was mainly due to higher cost of goods sold, mainly driven by rising costs due to inflationary and other macroeconomic pressures, as well as an increase in revenues with lower profitability from Anda.
North America Profit
Profit from our North America segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our North America segment in the first quarter of 2023 was $332 million, a decrease of 17% compared to $402 million in the first quarter of 2022. This decrease was mainly due to lower gross profit.
Europe Segment
Our Europe segment includes the European Union, the United Kingdom and certain other European countries.
The following table presents revenues, expenses and profit for our Europe segment for the three months ended March 31, 2023 and 2022:
|
|
Three months ended March 31, |
||||||
|
|
2023 |
|
2022 |
||||
|
|
(U.S. $ in millions / % of Segment Revenues) |
||||||
|
Revenues |
$ |
1,184 |
100% |
$ |
1,156 |
100% |
|
|
Gross profit |
|
655 |
55.3% |
|
694 |
60.0% |
|
|
R&D expenses |
|
53 |
4.5% |
|
58 |
5.0% |
|
|
S&M expenses |
|
187 |
15.8% |
|
196 |
17.0% |
|
|
G&A expenses |
|
70 |
5.9% |
|
59 |
5.1% |
|
|
Other income |
|
§ |
§ |
|
§ |
§ |
|
|
Segment profit* |
$ |
345 |
29.1% |
$ |
381 |
32.9% |
|
|
|
|
|
|
|
|
|
|
|
§ Represents an amount less than $0.5 million or 0.5%, as applicable. |
|||||||
|
* Segment profit does not include amortization and certain other items. |
|||||||
Revenues from our Europe segment in the first quarter of 2023 were $1,184 million, an increase of 2%, or $28 million, compared to the first quarter of 2022. In local currency terms, revenues increased by 9%, mainly due to higher revenues from generic products and generic product launches.
In the first quarter of 2023, revenues were negatively impacted by exchange rate fluctuations of $79 million, net of hedging effects, compared to the first quarter of 2022. Revenues in the first quarter of 2023 included $6 million from a negative hedging impact, which is included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our Europe segment by major products and activities for the three months ended March 31, 2023 and 2022:
|
|
|
Three months ended March 31, |
|
Percentage Change |
|
||||
|
|
|
2023 |
|
2022 |
|
2023-2022 |
|||
|
|
|
(U.S. $ in millions) |
|
|
|||||
|
Generic products |
|
$ |
932 |
|
$ |
876 |
|
6% |
|
|
AJOVY |
|
|
36 |
|
|
30 |
|
17% |
|
|
COPAXONE |
|
|
59 |
|
|
72 |
|
(17%) |
|
|
Respiratory products |
|
|
68 |
|
|
71 |
|
(4%) |
|
|
Other |
|
|
89 |
|
|
107 |
|
(17%) |
|
|
Total |
|
$ |
1,184 |
|
$ |
1,156 |
|
2% |
|
Generic products revenues (including OTC and biosimilar products) in our Europe segment in the first quarter of 2023, increased by 6% to $932 million, compared to the first quarter of 2022. In local currency terms, revenues increased by 12%, mainly due to higher revenues from generic and OTC products and from generic product launches.
AJOVY revenues in our Europe segment in the first quarter of 2023 increased by 17% to $36 million, compared to $30 million in the first quarter of 2022. In local currency terms, revenues increased by 28%, mainly due to growth in European countries in which AJOVY had previously been launched.
COPAXONE revenues in our Europe segment in the first quarter of 2023 decreased by 17% to $59 million, compared to the first quarter of 2022. In local currency terms, revenues decreased by 12%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products.
Respiratory products revenues in our Europe segment in the first quarter of 2023 decreased by 4% to $68 million compared to the first quarter of 2022. In local currency terms, revenues increased by 2%, mainly due to higher demand.
Europe Gross Profit
Gross profit from our Europe segment in the first quarter of 2023 was $655 million, a decrease of 6% compared to $694 million in the first quarter of 2022.
Gross profit margin for our Europe segment in the first quarter of 2023 decreased to 55.3%, compared to 60.0% in the first quarter of 2022. This decrease was mainly due to higher cost of goods sold, mainly driven by rising costs due to inflationary and other macroeconomic pressures.
Europe Profit
Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our Europe segment in the first quarter of 2023 was $345 million, a decrease of 9%, compared to $381 million in the first quarter of 2022. This decrease was mainly due to lower gross profit as described above and exchange rate fluctuations.
International Markets Segment
Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments.
The following table presents revenues, expenses and profit for our International Markets segment for the three months ended March 31, 2023 and 2022:
|
|
Three months ended March 31, |
||||||
|
|
2023 |
|
2022 |
||||
|
|
(U.S. $ in millions / % of Segment Revenues) |
||||||
|
Revenues |
$ |
492 |
100% |
$ |
492 |
100% |
|
|
Gross profit |
|
262 |
53.2% |
|
286 |
58.1% |
|
|
R&D expenses |
|
20 |
4.0% |
|
20 |
4.0% |
|
|
S&M expenses |
|
98 |
19.8% |
|
97 |
19.8% |
|
|
G&A expenses |
|
31 |
6.4% |
|
29 |
5.9% |
|
|
Other income |
|
(1) |
§ |
|
(40) |
(8.1%) |
|
|
Segment profit* |
$ |
114 |
23.1% |
$ |
179 |
36.4% |
|
|
|
|
|
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items. |
|||||||
|
§ Represents an amount less than 0.5%. |
|||||||
Revenues from our International Markets segment in the first quarter of 2023 were $492 million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 8% compared to the first quarter of 2022.
In the first quarter of 2023, revenues were negatively impacted by exchange rate fluctuations of $41 million, net of hedging effects, compared to the first quarter of 2022. Revenues in the first quarter of 2023 included a minimal hedging impact, compared to a positive hedging impact of $12 million in the first quarter of 2022, which is included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our International Markets segment by major products and activities for the three months ended March 31, 2023 and 2022:
|
|
|
|
|
|
||||
|
|
|
Three months ended March 31, |
|
Percentage Change |
||||
|
|
|
2023 |
|
2022 |
|
2023-2022 |
||
|
|
|
(U.S. $ in millions) |
|
|
||||
|
Generic products |
|
$ |
400 |
|
$ |
388 |
|
3% |
|
AJOVY |
|
|
10 |
|
|
6 |
|
74% |
|
COPAXONE |
|
|
12 |
|
|
10 |
|
16% |
|
Other |
|
|
70 |
|
|
88 |
|
(20%) |
|
Total |
|
$ |
492 |
|
$ |
492 |
|
§ |
|
|
|
|
|
|
|
|
|
|
|
§ Represents an amount less than 0.5%. |
||||||||
Generic products revenues in our International Markets segment in the first quarter of 2023, which include OTC products, increased by 3% in U.S. dollars to $400 million. In local currency terms, revenues increased by 9% compared to the first quarter of 2022, mainly due to higher revenues in certain markets, as well as price increases largely as a result of rising costs due to inflationary pressure, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.
AJOVY was launched in certain markets in our International Markets segment, including in Japan in August 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the first quarter of 2023 were $10 million, compared to $6 million in the first quarter of 2022, mainly due to growth in volume.
Contacts
IR Contacts
Ran Meir +1 (267) 468-4475
Yael Ashman +972 (3) 914 8262
Sanjeev Sharma +1 (267) 658-2700
PR Contacts
Kelley Dougherty +1 (973) 832-2810
Eden Klein +972 (3) 906 2645